[go: up one dir, main page]

WO2025128057A1 - Formulation en sachet comprenant du brivaracétam - Google Patents

Formulation en sachet comprenant du brivaracétam Download PDF

Info

Publication number
WO2025128057A1
WO2025128057A1 PCT/TR2024/051508 TR2024051508W WO2025128057A1 WO 2025128057 A1 WO2025128057 A1 WO 2025128057A1 TR 2024051508 W TR2024051508 W TR 2024051508W WO 2025128057 A1 WO2025128057 A1 WO 2025128057A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
sodium
formulation according
mixtures
sachet formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/TR2024/051508
Other languages
English (en)
Inventor
Fatih Sunel
Fadime Bilgehan ATAK
Seval Ataman
Ozlem YAZICI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of WO2025128057A1 publication Critical patent/WO2025128057A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to a sachet formulation comprising brivaracetam or a pharmaceutically acceptable salt thereof, and at least one sweetener, wherein the amount of brivaracetam is between 1.0% and 15.0% by weight in the total formulation.
  • the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process of preparing the sachet formulation.
  • brivaracetam (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-l-yl] butanamide and its chemical structure is shown in the Formula I.
  • Brivaracetam is a white to off-white crystalline powder. It is very soluble in water, buffer (pH 1.2, 4.5 and 7.4), ethanol, methanol, and glacial acetic acid. It is freely soluble in acetonitrile and acetone and soluble in toluene. It is very slightly soluble in n-hexane. Additionally, brivaracetam is an extremely viscous compound (adhesive capacity).
  • Brivaracetam is commercially approved in the form of tablets, oral solution and injection, in the USA under the brand name Briviact and are marketed by UCB Pharma.
  • Brivaracetam Due to Brivaracetam's high adhesion properties, we wanted to create a simple and homogeneous sachet formulation by using a several excipients. In this way, the disadvantages of the active substance will be eliminated and patient compliance will be ensured by providing ease of use. Creating sachet formulations provides a more convenient and easier method for active substances that have such disadvantages. Brivaracetam has low melting point that result in some challenges in tablet coating such as pitting of the coating layer. Since the use of sachet formulation does not contain a coating, it has become advantageous in terms of physical stability as well as patient compliance.
  • Brivaracetam has a bitter taste so this is a problem that should be overcome. Therefore, it is needed to develop a sachet formulation which has a desired acceptable taste for patients.
  • a sachet formulation was developed to cater for patients who have difficulty swallowing tablets.
  • the formulation was developed in order to create a solution of acceptable taste, consistency and stability.
  • the main object of the present invention provides a sachet formulation comprising brivaracetam having the desired stability, content uniformity and dissolution profile.
  • Another object of the present invention is to eliminate the problems related to active ingredients and to obtain a solution with pleasant taste when the sachet formulation dissolves in water.
  • Another object of the present invention is to provide a process of preparing a sachet formulation comprising brivaracetam which is simple and cost-effective process.
  • the sachet formulations with a good solubility result in a homogenous mixture.
  • Taste is one of the most important parameters governing patient compliance for sachet formulations. It has been surprisingly found that using a sachet formulation comprising brivaracetam with an excipient that is a sweetener, we have achieved a formulation that provides the desired stability, dissolution profile and gives the tablet a good taste.
  • sachet formulations have become an issue with increasing importance in terms of patient compliance as compared to conventional solid dosage forms such as capsules and tablets. This issue is more important in terms of patients having difficulty in swallowing. For these reasons, sachet formulations are one of the advantageous routes for administering the drugs comprising brivaracetam and provide a higher patient compliance along with recommended pharmaceutical therapies.
  • a sachet formulation comprises brivaracetam or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable sweetener, wherein the amount of brivaracetam is between 0.1% and 15.0% by weight in the total formulation.
  • the amount of brivaracetam is between 1.0% and 7.0% by weight in the total formulation.
  • the high adhesion properties of brivaracetam its use at this ratio provided the desired dissolution profile.
  • Suitable sweeteners are selected from the group comprising sucralose, sucrose, mannitol, saccharin, neotame, xylose, maltitol, aspartame, maltol, sorbitol, glucose, menthol, peppermint and xylitol or mixtures thereof.
  • the sweetener is sucralose or sucrose or mannitol or saccharin or neotame or mixtures thereof.
  • the sweeteners used also help to provide the stability of the sachet form.
  • a sachet formulation further comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising flavouring agent, pH agent, acid source, gas generating agent, binders or mixtures thereof.
  • Suitable flavouring agents are selected from the group comprising orange, lemon, cherry, menthol, peppermint, cinnamon, chocolate, vanillin, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries or mixtures thereof.
  • the flavouring agent is orange or lemon or mixtures thereof.
  • Suitable pH agents are selected from the group comprising monosodium citrate, anhydrous disodium hydrogen phosphate, potassium carbonate, anhydrous sodium dihydrogen phosphate, dibasic potassium sulfate, nicotinic acid, dilute hydrochloric acid, glacial acetic acid, monobasic potassium phosphate, phosphoric acid, adipic acid, sodium acetate, sodium dihydrogen phosphate dihydrate, tribasic sodium phosphate or mixtures thereof.
  • the pH agent is monosodium citrate.
  • Suitable acid sources are selected from the group comprising citric acid anhydrous, malic acid, maleic acid, tartaric acid, nicotinic acid, dilute hydrochloric acid, glacial acetic acid, ascorbic acid, acetylsalicylic acid, lactic acid, adipic acid, tartaric acid or mixtures thereof.
  • the acid source is citric acid anhydrous or malic acid or maleic acid or tartaric acid or mixtures thereof.
  • Suitable gas generating agents are selected from the group comprising sodium bicarbonate, sodium carbonate, calcium carbonate, aluminum potassium sulfate, anhydrous disodium hydrogen phosphate, potassium bicarbonate, anhydrous sodium dihydrogen phosphate, dibasic potassium sulfate, monobasic potassium phosphate, sodium carbonate, sodium glycine carbonate sodium citrate, sodium dihydrogen phosphate dihydrate, tribasic sodium phosphate or mixtures thereof.
  • the gas generating agent is sodium bicarbonate or sodium carbonate or calcium carbonate or mixtures thereof.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, hydroxypropyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl methyl cellulose, carboxy methyl cellulose, methyl cellulose, guar gum, polymethacrylates, methacrylate polymers, polysaccharides, poloxamer, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the binder is polyvinylpyrrolidone.
  • Sachet formulation may be achieved using the dry and wet granulation method, resulting in a simple and low-cost production method.
  • Brivaracetam is extremely prone to sticking and clumping due to the high adhesion during the preparation process, which poses major problems for the appearance and ingredient integrity of the final product.
  • Powder is granulated with povidone k30 in water solution and dried

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation en sachet comprenant du brivaracétam ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un édulcorant, la quantité de brivaracétam étant comprise entre 1,0 % et 15,0 % en poids dans la formulation totale. La présente invention concerne également un procédé simple, rapide, économique, économe en temps et industriellement pratique pour la préparation de la formulation en sachet.
PCT/TR2024/051508 2023-12-13 2024-12-09 Formulation en sachet comprenant du brivaracétam Pending WO2025128057A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2023/017170A TR2023017170A1 (tr) 2023-12-13 2023-12-13 Bri̇varasetam i̇çeren bi̇r saşe formülasyonu
TR2023/017170 2023-12-13

Publications (1)

Publication Number Publication Date
WO2025128057A1 true WO2025128057A1 (fr) 2025-06-19

Family

ID=96058208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2024/051508 Pending WO2025128057A1 (fr) 2023-12-13 2024-12-09 Formulation en sachet comprenant du brivaracétam

Country Status (2)

Country Link
TR (1) TR2023017170A1 (fr)
WO (1) WO2025128057A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006929A1 (fr) * 2008-07-16 2010-01-21 Ucb Pharma, S.A. Compositions pharmaceutiques renfermant du lévétiracétam
US8460712B2 (en) * 2008-11-18 2013-06-11 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
US20220226368A1 (en) * 2019-10-02 2022-07-21 Intas Pharmaceuticals Ltd. Essentially sodium-free effervescent solid pharmaceutical compositions
WO2023157025A1 (fr) * 2022-02-17 2023-08-24 Zenvision Pharma Llp Nouvelle composition pharmaceutique ou nutraceutique pour le traitement ou la prévention de l'épilepsie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006929A1 (fr) * 2008-07-16 2010-01-21 Ucb Pharma, S.A. Compositions pharmaceutiques renfermant du lévétiracétam
US8460712B2 (en) * 2008-11-18 2013-06-11 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
US20220226368A1 (en) * 2019-10-02 2022-07-21 Intas Pharmaceuticals Ltd. Essentially sodium-free effervescent solid pharmaceutical compositions
WO2023157025A1 (fr) * 2022-02-17 2023-08-24 Zenvision Pharma Llp Nouvelle composition pharmaceutique ou nutraceutique pour le traitement ou la prévention de l'épilepsie

Also Published As

Publication number Publication date
TR2023017170A1 (tr) 2025-06-23

Similar Documents

Publication Publication Date Title
JP4435424B2 (ja) 口腔内で速やかに崩壊する錠剤
JP4551092B2 (ja) 口腔内速崩壊性錠剤
KR101865776B1 (ko) 전립선암 또는 유방암의 치료를 위한 디에틸스틸베스트롤의 투여 형태 및 용도
JP2000504028A (ja) 口内薬剤輸送系
JPS62149615A (ja) 鎮痛作用を有する沸騰組成物
JPWO2000047233A1 (ja) 口腔内で速やかに崩壊する錠剤
JPS6341420A (ja) 鎮痛作用を有する医薬組成物
JP6820116B2 (ja) レボセチリジンを含む医薬組成物
EA021645B1 (ru) Твердая дозированная форма в виде таблетки и способ её приготовления
KR101360526B1 (ko) 개선된 약력학적 특성을 갖는 약물 제형
BG64348B1 (bg) Лекарствена форма за гълтане, съдържаща парацетамол
KR20150002453A (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2025128057A1 (fr) Formulation en sachet comprenant du brivaracétam
EP4125824A1 (fr) Formulation en sachet comprenant de la metformine et de la dapagliflozine
KR101046789B1 (ko) 안정성이 개선된 암로디핀 속붕해성 정제 및 그의 제조방법
EP4570238A1 (fr) Formulation de sachet comprenant du brivaracétam
US20230330079A1 (en) Orally-disintegrating film comprising naratriptan
JP4358117B2 (ja) 口腔内速崩壊錠
JP3899522B2 (ja) 苦味が低減されたプランルカスト水和物を含有する製剤
WO2006109737A1 (fr) Préparation contenant du pranlukast hydraté ayant une amertume réduite
JP2017081850A (ja) 造粒物及びこれを含む経口製剤並びに造粒物及び経口製剤の製造方法
WO2013098399A1 (fr) Formulation de mozavaptan
JP2002536401A (ja) メタミゾール含有起泡性医薬組成物
Comoglu et al. 18 Granulation and Production Approaches of Orally Disintegrating Tablets
WO2022153334A1 (fr) Formes galéniques transmucosales du foscarnet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24904548

Country of ref document: EP

Kind code of ref document: A1